REGENXBIO (NASDAQ:RGNX) Given "Buy" Rating at Chardan Capital

REGENXBIO (NASDAQ:RGNX - Get Free Report)'s stock had its "buy" rating reissued by Chardan Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $52.00 price objective on the biotechnology company's stock.

Several other equities analysts have also weighed in on the company. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Morgan Stanley reissued an "overweight" rating and set a $22.00 target price on shares of REGENXBIO in a research report on Friday, November 15th. Royal Bank of Canada reissued an "outperform" rating and set a $30.00 target price on shares of REGENXBIO in a research report on Tuesday, January 21st. The Goldman Sachs Group cut shares of REGENXBIO from a "buy" rating to a "neutral" rating and cut their price target for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Finally, Raymond James began coverage on shares of REGENXBIO in a research note on Friday, February 7th. They set an "outperform" rating and a $27.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $33.88.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX traded up $0.80 during midday trading on Friday, hitting $7.80. 1,566,918 shares of the stock were exchanged, compared to its average volume of 695,741. REGENXBIO has a 52-week low of $5.62 and a 52-week high of $23.14. The business's fifty day simple moving average is $7.29 and its two-hundred day simple moving average is $8.97. The company has a market capitalization of $386.45 million, a PE ratio of -1.55 and a beta of 1.35.

Remove Ads

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The business had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. As a group, equities analysts anticipate that REGENXBIO will post -4.84 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC raised its position in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 2,510 shares during the last quarter. FMR LLC grew its position in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after buying an additional 1,656 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of REGENXBIO during the 4th quarter valued at about $54,000. Dynamic Technology Lab Private Ltd bought a new position in shares of REGENXBIO during the 4th quarter valued at about $79,000. Finally, Laurion Capital Management LP bought a new stake in REGENXBIO in the 4th quarter valued at approximately $79,000. Institutional investors own 88.08% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.